A new trading day began on Tuesday, with Myriad Genetics, Inc (NASDAQ: MYGN) stock price up 3.91% from the previous day of trading, before settling in for the closing price of $4.86. MYGN’s price has ranged from $3.81 to $29.30 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -106.08%. With a float of $87.40 million, this company’s outstanding shares have now reached $92.20 million.
In an organization with 2700 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 70.01%, operating margin of -14.98%, and the pretax margin is -15.27%.
Myriad Genetics, Inc (MYGN) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Diagnostics & Research Industry. The insider ownership of Myriad Genetics, Inc is 5.19%, while institutional ownership is 102.41%. The most recent insider transaction that took place on Oct 11 ’24, was worth 343,950. In this transaction President and CEO of this company sold 15,000 shares at a rate of $22.93, taking the stock ownership to the 962,378 shares. Before that another transaction happened on Oct 11 ’24, when Company’s Officer proposed sale 15,000 for $22.93, making the entire transaction worth $343,950.
Myriad Genetics, Inc (MYGN) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -106.08% per share during the next fiscal year.
Myriad Genetics, Inc (NASDAQ: MYGN) Trading Performance Indicators
Here are Myriad Genetics, Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.12, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach 0.15 in one year’s time.
Technical Analysis of Myriad Genetics, Inc (MYGN)
Let’s dig in a bit further. During the last 5-days, its volume was 1.91 million. That was better than the volume of 1.72 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 30.32%.
During the past 100 days, Myriad Genetics, Inc’s (MYGN) raw stochastic average was set at 10.62%, which indicates a significant decrease from 45.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.63% in the past 14 days, which was lower than the 107.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.58, while its 200-day Moving Average is $13.68. However, in the short run, Myriad Genetics, Inc’s stock first resistance to watch stands at $5.12. Second resistance stands at $5.20. The third major resistance level sits at $5.29. If the price goes on to break the first support level at $4.95, it is likely to go to the next support level at $4.86. Assuming the price breaks the second support level, the third support level stands at $4.78.
Myriad Genetics, Inc (NASDAQ: MYGN) Key Stats
With a market capitalization of 465.49 million, the company has a total of 92,177K Shares Outstanding. Currently, annual sales are 837,600 K while annual income is -127,300 K. The company’s previous quarter sales were 195,900 K while its latest quarter income was -100 K.
